PGLYRP2

Across TCGA pan-cancer cohorts, PGLYRP2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PGLYRP2 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PGLYRP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PGLYRP2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

COAD, LUAD, and CCRCC are the cancer types where PGLYRP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.880	1.000	.020	60	view →
LUAD	DFS	Median	III,IV	0.485	0.995	.003	36	view →
CCRCC	DFS	Median	III,IV	0.912	0.503	<.001	29	view →
LSCC	DFS	Median	II,III,IV	0.840	1.000	.007	6	view →
HNSC	OS	Median	II,III,IV	0.950	1.000	.014	4	view →
PDAC	DFS	Median	IV	0.234	0.766	.026	4	view →
GBM	DFS	Median	All	0.286	0.461	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PGLYRP2–COAD (DFS)

Open the COAD breakdown →